Skip to main content

Zoetis Value Stock - Dividend - Research Selection


ISIN: US98978V1035 , WKN: A1KBYX

Market price date:
Market price:  

Fundamental data and company key figures of the share

Annual reports in
Key figures
Cash flow
Net operating cash flow
Capital Expenditures
Free cash flow
Balance sheet
Total Equity
Liabilities & Shareholders equity
Income statement
Net income
Eps (diluted)
Diluted shares outstanding
Net sales/revenue

Fundamental ratios calculated on:

Key figures
Cash flow
Balance sheet
Income statement
Div. Yield%

Do you want to do make a detailed fundamental analysis of this stock?

✓ NEW Fundamental API Access to 500 data points per month
Fundamental data up to 25 years
Comparison to all other stocks by the FScore
Time saving!

How our site works ...

Non-binding 7 days without automatic subscription
 No termination required after the free week
Finanzoo fundamental analysis
Data updated daily
Virtual depots
Share alarms via email
Subscription can be canceled at any time at the end of the month 
Choice of desired shares
Over 2000 stock analyzes available
Bitcoin payment possible if you do not want to subscribe

Price for monthly subscription $ 19.99 / month including VAT.

Market Capitalization USD
Raw Data Source
Stock Split

Description of the company

Zoetis Inc. is a global leader in the discovery, development, manufacture and commercialization of animal health medicines and vaccines, with a focus on both livestock and companion animals. We have a diversified business, commercializing products across eight core species: cattle, swine, poultry, sheep and fish (collectively, livestock) and dogs, cats and horses (collectively, companion animals); and within five major product categories: anti-infectives, vaccines, parasiticides, medicated feed additives and other pharmaceuticals. For more than 60 years, as a business unit of Pfizer Inc. (Pfizer), and since 2013 as an independent public company, we have been committed to enhancing the health of animals and bringing solutions to our customers who raise and care for them. We were incorporated in Delaware in July 2012. The address of our principal executive offices is 10 Sylvan Way, Parsippany, New Jersey 07054. Unless the context requires otherwise, references to “Zoetis,” “the company,” “we,” “us” or “our” in this Annual Report on Form 10-K for the fiscal year ended December 31, 2016 (2016 Annual Report) refer to Zoetis Inc., a Delaware corporation, and its subsidiaries. In addition, unless the context requires otherwise, references to “Pfizer” in this 2016 Annual Report refer to Pfizer Inc., a Delaware corporation, and its subsidiaries. On February 1, 2013, our Class A common stock began trading on the New York Stock Exchange (NYSE) under the symbol “ZTS.” On February 6, 2013, an initial public offering (IPO) of our Class A common stock was completed, which represented approximately 19.8% of our total outstanding shares, with Pfizer owning the remaining outstanding shares. On June 24, 2013, an exchange offer was completed whereby Pfizer shareholders exchanged a portion of Pfizer common stock for Zoetis common stock, resulting in the full separation of Zoetis and the disposal of Pfizer's entire ownership and voting interest in Zoetis. Operating Segments The animal health medicines and vaccines market is characterized by meaningful differences in customer needs across different regions. This is due to a variety of factors, including: • economic differences, such as standards of living in developed markets as compared to emerging markets; • cultural differences, such as dietary preferences for different animal proteins, pet ownership preferences and pet care standards; • epidemiological differences, such as the prevalence of certain bacterial and viral strains and disease dynamics; • treatment differences, such as utilization of different types of medicines and vaccines, as well as the pace of adoption of new technologies; • environmental differences, such as seasonality, climate and the availability of arable land and fresh water; and • regulatory differences, such as standards for product approval and manufacturing. As a result of these differences, among other things, we organize and operate our business in two segments: the United States and International. Within each of these operating segments, we offer a diversified product portfolio for both livestock and companion animal customers so that we can capitalize on local trends and customer needs. Our operating segments are: • United States with revenue of $2,447 million, or 50% of total revenue for the year ended December 31, 2016; and • International with revenue of $2,390 million, or 49% of total revenue for the year ended December 31, 2016.
The Finanzoo GmbH assumes no liability for the accuracy of the information! All information is provided without warranty. Sources::,,


Zoetis to Host Webcast and Conference Call on First Quarter 2023 Financial Results

PARSIPPANY, N.J., March 30, 2023--Zoetis Inc. (NYSE:ZTS) will host a webcast and conference call at 8:30 a.m. (ET) on Thursday, May 4, 2023. Chief Executive Officer Kristin Peck and Executive Vice President and Chief Financial Officer Wetteny Joseph will review first quarter 2023 financial results and respond to questions from financial analysts during the call.

Zoetis Stock Could Rise 30% as People Spend More on Pets

Zoetis is in the enviable position of being the world’s only pure-play global animal-health company at a time when spending on pets and livestock is rising. A pullback in its shares makes this a good time to buy.

Wednesday Sector Laggards: Healthcare, Services

Looking for stock market analysis and research with proves results? offers in-depth financial research with over 30years of proven results.

Zoetis Stock Sees IBD Relative Strength Rating Improve To 73

A Relative Strength Rating upgrade for Zoetis shows improving technical performance. Will it continue?

Prescription for Profit: 3 ���Strong Buy��� Healthcare Stocks Analysts Love

Looking for stock market analysis and research with proves results? offers in-depth financial research with over 30years of proven results.

Unusual Call Option Trade in Zoetis (ZTS) Worth $785.75K


Notable Wednesday Option Activity: ZTS, ACN, ALB

Looking for stock market analysis and research with proves results? offers in-depth financial research with over 30years of proven results.

NFJ: Non-Leveraged Hybrid Fund At A Wide Discount

The Virtus Dividend Interest & Premium Strategy Fund primarily invests in equity investments but also incorporates convertible securities. See our take on NFJ here.

Zoetis (ZTS) Dips More Than Broader Markets: What You Should Know

Zoetis (ZTS) closed at $164.47 in the latest trading session, marking a -1.11% move from the prior day.

The Zacks Analyst Blog Highlights Nike, Salesforce, Zoetis, Archer-Daniels-Midland and Trane Technologies

Nike, Salesforce, Zoetis, Archer-Daniels-Midland and Trane Technologies are part of the Zacks top Analyst Blog.